Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study
Background Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.Objectives To characterize anti-P...
שמור ב:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2026-03-01
|
| סדרה: | Journal for ImmunoTherapy of Cancer |
| גישה מקוונת: | https://jitc.bmj.com/content/14/3/e014564.full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
